A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

K Bertelsen; A Jakobsen; J E Andersen; S Ahrons; P H Pedersen; H Kiaer; E Arffmann; P Bichel; E Boestofte; I Strøyer

doi:10.1016/0090-8258(87)90210-1

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

Gynecol Oncol. 1987 Oct;28(2):161-9. doi: 10.1016/0090-8258(87)90210-1.

Authors

K Bertelsen¹, A Jakobsen, J E Andersen, S Ahrons, P H Pedersen, H Kiaer, E Arffmann, P Bichel, E Boestofte, I Strøyer, et al.

Affiliation

¹ Danish Ovarian Cancer Group, Department of Oncology, University Hospital, Odense, Denmark.

PMID: 3311924
DOI: 10.1016/0090-8258(87)90210-1

Abstract

Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma / drug therapy*
Carcinoma / mortality
Cisplatin / administration & dosage
Clinical Trials as Topic
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Humans
Middle Aged
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Random Allocation

Substances

Doxorubicin
Cyclophosphamide
Cisplatin